Pharmaceutical firm Sanofi has upgraded its full-year 2026 financial guidance. This follows a strong second-quarter performance marked by double-digit top-line growth and a surging business earnings per share.
For the three months to June 30, 2026, net sales reached €11.597 billion. Marking a 17.8% increase at constant exchange rates (CER) and up 16.0% on an actual basis. The robust quarterly performance pushed first-half (H1) sales to €22.106 billion, representing a 15.7% CER expansion year-on-year.
Business Operating Income (BOI) for the quarter leapt 35.8% at CER to €3.291 billion. Therefore pushing business operating margins up by 3.8 percentage points to 28.4%. Subsequently, Sanofi expects full-year 2026 sales to grow by around 10% at CER. Business EPS is projected to grow slightly faster than sales.
Dupixent Breaks €5bn Quarterly Threshold
The main engine behind Sanofi’s quarterly acceleration is its flagship immunology treatment, Dupixent. Specifically, sales grew 37.6% to €5.2 billion, crossing the €5 billion quarterly threshold for the first time in the drug’s history. Sanofi expects Dupixent to reach approximately €25 billion in annual sales by 2030 (at CER).
Beyond Dupixent, Sanofi’s portfolio of recent pharmaceutical launches, including Ayvakit, ALTUVIIIO, and Sarclisa, experienced a 48.3% sales surge to €1.3 billion. Therefore the group projects that its launch portfolio will contribute roughly €10 billion annually by 2030.
Conversely, vaccine sales contracted by 4.7% to €1.1 billion. This largely reflects a high basis of comparison in influenza vaccines from late-season one-offs in 2025.
Regional Sales Split
Growth was heavily anchored by the United States. Here, commercial demand for launch assets and Dupixent drove a sharp revenue expansion:
United States: Sales reached €6.344 billion (+33.5% CER). The rise was boosted by strong pharma launches and the integration of newly acquired Heplisav-B in vaccines.
Europe: Net sales edged up 1.3% CER to €2.141 billion. However, launch momentum was partially offset by legacy product declines.
Rest of World: Revenue grew 3.7% CER to €3.112 billion. Within the region, China sales dropped 4.9% to €676 million due to lower birth rates impacting primary paediatric vaccines. But, pharma launches (Sarclisa, Rezurock, and Myqorzo) gained traction.
Leadership Strategy: Pipeline Discipline & Strategic Focus
The Q2 earnings report marks one of the first major operational milestones under Belén Garijo, who assumed the role of Chief Executive Officer in late April 2026.
Garijo noted that her initial months have focused on initiating an accelerated transformation roadmap to sharpen R&D efficiency and focus capital on high-conviction assets.
Speaking on the quarterly performance, Belén Garijo commented:
“We delivered double-digit sales growth and strong business EPS growth in Q2… My first months as CEO have focused on assessing the challenges facing Sanofi and working on an accelerated transformation roadmap that leverages our commercial strengths and focuses on the need for R&D and pipeline improvements.
“We have taken the first decisive steps on pipeline prioritisation and recently, we appointed a focused Executive Committee aligned with the strategic priorities. Looking ahead, we’re confident in our trajectory of profitable growth.”
Pipeline Prioritisation Decisions
During the quarter, Sanofi achieved seven regulatory approvals across immunology, oncology, rare diseases, and neurology, alongside positive Phase 3 readouts for Nexviazyme (infantile-onset Pompe disease) and amlitelimab (atopic dermatitis maintenance).
However, alongside these milestones, Garijo signaled clear capital discipline by terminating lower-conviction R&D assets:
Amlitelimab will not progress to global regulatory submissions for atopic dermatitis.
Clinical development programs for itepekimab and balinatunfib have been formally discontinued.
R&D expenditure for the quarter increased by 17.9% to €2.2 billion, reflecting pipeline restructuring costs, while selling and general administrative (SG&A) expenses rose 9.0% to €2.5 billion following recent M&A integrations.
Capital Allocation & Impact Milestones
Sanofi confirmed the completion of its €1 billion share buyback programme during the first half of the year.
On the sustainability front, the pharmaceutical group expanded its Impact® global health portfolio into 30 underserved nations, progressing toward its Global Health Unit goal of treating two million patients with non-communicable diseases in low-income regions by 2030.
Key Takeaways for Commercial & Healthcare Leaders
Commercial Execution Drives Scale: Building a focused commercial machine around core launch assets (Ayvakit, Sarclisa, ALTUVIIIO) can offset legacy product erosion.
R&D Discipline Over Volume: High-performing healthcare companies are actively culling clinical programmes early to reallocate resource toward high-margin, high-impact therapeutics.
US Market Multiplier: The US market remains the primary growth driver for global pharma, accounting for over 54% of Sanofi’s total Q2 revenue.
